Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
5.50
-0.06 (-1.08%)
At close: Jan 28, 2026, 4:00 PM EST
5.53
+0.03 (0.55%)
After-hours: Jan 28, 2026, 4:16 PM EST
Atara Biotherapeutics Employees
Atara Biotherapeutics had 38 employees as of September 30, 2025. The number of employees decreased by 121 or -76.10% compared to the same quarter last year.
Employees
38
Change
-121
Growth
-76.10%
Revenue / Employee
$3,998,158
Profits / Employee
$615,816
Market Cap
39.66M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 38 | -121 | -76.10% |
| Jun 30, 2025 | 38 | -127 | -76.97% |
| Mar 31, 2025 | 89 | -84 | -48.55% |
| Dec 31, 2024 | 153 | -72 | -32.00% |
| Sep 30, 2024 | 159 | -149 | -48.38% |
| Jun 30, 2024 | 165 | -152 | -47.95% |
| Mar 31, 2024 | 173 | -157 | -47.58% |
| Dec 31, 2023 | 225 | -109 | -32.63% |
| Sep 30, 2023 | 308 | -32 | -9.41% |
| Jun 30, 2023 | 317 | -117 | -26.96% |
| Mar 31, 2023 | 330 | -240 | -42.11% |
| Dec 31, 2022 | 334 | -244 | -42.21% |
| Sep 30, 2022 | 340 | -238 | -41.18% |
| Jun 30, 2022 | 434 | -124 | -22.22% |
| Mar 31, 2022 | 570 | 90 | 18.75% |
| Dec 31, 2021 | 578 | 141 | 32.27% |
| Sep 30, 2021 | 578 | 149 | 34.73% |
| Jun 30, 2021 | 558 | 133 | 31.29% |
| Mar 31, 2021 | 480 | 71 | 17.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 123 |
| Generation Bio Co. | 115 |
| Passage Bio | 60 |
| Lisata Therapeutics | 26 |
| Lantern Pharma | 24 |
| Reviva Pharmaceuticals Holdings | 14 |
| Apollomics | 13 |
| Rein Therapeutics | 11 |
ATRA News
- 16 days ago - Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel) - Business Wire
- 2 months ago - Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress - Business Wire
- 3 months ago - Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PRNewsWire
- 4 months ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga
- 5 months ago - Atara Biotherapeutics Announces Changes to Its Board of Directors - Business Wire
- 6 months ago - Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress - Business Wire
- 6 months ago - Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PRNewsWire
- 6 months ago - Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease - Business Wire